TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cutia Therapeutics ( (HK:2487) ) has issued an update.
Cutia Therapeutics, a company incorporated in the Cayman Islands, has announced changes in its board of directors. Mr. Tao Tak Yan Dennis has resigned from his position as an independent non-executive director and from his roles in the audit and nomination committees to focus on personal commitments. The company has appointed Mr. Zhang Zhisong as the new independent non-executive director, effective August 28, 2025. Mr. Zhang brings extensive financial experience from previous roles at TUHU Car Inc., Goldman Sachs, Citigroup, Merrill Lynch, and Deutsche Bank. His appointment is expected to strengthen the company’s governance and strategic direction.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Average Trading Volume: 1,252,347
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$3.14B
See more insights into 2487 stock on TipRanks’ Stock Analysis page.